My Blue Dots – Page 16

New book provides recommendations for addressing cancer among Latinos

MyBlueDots3 weeks ago01 mins

With cancer still rising in the U.S. Latino population, leaders at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and national cancer experts have published an online book with innovative recommendations to reduce Latino cancer.

Analysis tackles the question of how many attempts it takes to quit different substances

MyBlueDots1 week ago01 mins

Relapse is common when someone is trying to quit, regardless of whether they’re giving up opioids or alcohol or cigarettes. To better inform treatment, researchers with the Fralin Biomedical Research Institute at VTC’s Addiction Recovery Research Center wanted to better understand how the experience of quitting differed across substances.

What you need to know about HMPV

MyBlueDots4 weeks ago01 mins

Reports that cases of a flu-like virus called HMPV are rising in China have sparked concern, but experts have dismissed fears that the situation is comparable to the beginnings of COVID-19 five years ago.

MyBlueDots

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

MyBlueDots3 weeks ago01 mins

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and

MyBlueDots

Merck’s GARDASIL® Receives Expanded Approval for Males in China

MyBlueDots4 weeks ago01 mins

RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck’s GARDASIL® Receives Expanded Approval for Males in China

MyBlueDots

MeMed Expands Advisory Board with Key Leaders to Advance Host-Response Diagnostics for Sepsis and AMR

MyBlueDots4 weeks ago01 mins

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

MyBlueDots

Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

MyBlueDots4 weeks ago01 mins

LEIDEN, Netherlands–(BUSINESS WIRE)– #Adults–Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with n

‘Unprecedented’ level of control allows person without use of limbs to operate virtual quadcopter

MyBlueDots2 weeks ago01 mins

A brain-computer interface, surgically placed in a research participant with tetraplegia, paralysis in all four limbs, provided an unprecedented level of control over a virtual quadcopter—just by thinking about moving his unresponsive fingers.

MyBlueDots

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

MyBlueDots4 weeks ago01 mins

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa

Suicidal behavior found to be more common among construction workers

MyBlueDots4 weeks ago01 mins

A study conducted at the University of Gothenburg shows that male construction workers have a 50% higher risk of suicide attempts and suicide. The findings confirm that suicidal behavior is more common among men in professions with low educational requirements.

Useful _Links

GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds

ONI Launches Aplo Scope to Revolutionize Single Molecule Super-Resolution Microscopy

DNA repair pathways reveal how tumor cells die after radiotherapy

Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics

Early intervention with iron delivered intravenously during pregnancy found safe and effective treatment for anemia

Jackson Healthcare Named to Forbes List of America’s Top Private Companies

New book provides recommendations for addressing cancer among Latinos

Analysis tackles the question of how many attempts it takes to quit different substances

What you need to know about HMPV

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Merck’s GARDASIL® Receives Expanded Approval for Males in China

MeMed Expands Advisory Board with Key Leaders to Advance Host-Response Diagnostics for Sepsis and AMR

Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

‘Unprecedented’ level of control allows person without use of limbs to operate virtual quadcopter

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Suicidal behavior found to be more common among construction workers

World News

Useful Links

Health

Business

Entertainment

About Us